Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Treatment of Gastroesophageal Cancer
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Treatment of Gastroesophageal Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (10 July 2023) | Viewed by 5184

Special Issue Editors

Dr. Ofer Margalit

E-Mail Website
Guest Editor
1. Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel
2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Interests: gastroesophageal cancers; gastric cancer
Prof. Dr. Aviram Nissan

E-Mail Website
Guest Editor
1. Department of General and Oncological Surgery-Surgery C, Sheba Medical Center, Tel-Hashomer, Israel
2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Interests: gastroesophageal cancers; gastric cancer

Special Issue Information

Dear Colleagues,

Treatment of gastroesophageal cancer has progressed dramatically during recent years. Immunotherpay is now a valid treatment option for microsatellite unstable (MSI high) or mismatch-repair-deficient (MMR-D) tumors and for those tumors that express high levels of PD-L1, measured using the combined positive score (CPS). For tumors that overexpress the HER2 protein, new drugs are now available, mainly novel antibody–drug conjugates (ADCs). Advances were also made in developing more efficient ways to administer intraperitoneal chemotherapy. PIPAC (pressurized intraperitoneal aerosol chemotherapy) is a groundbreaking method of delivering chemotherapy, enabling control of peritoneal metastasis with fewer adverse events compared with systemic chemotherpay. In this Special Issue, we welcome authors to submit papers on the recent advances in treatment of gastroesophageal cancer in terms of both systemic treatments and surgical approaches.

Dr. Ofer Margalit
Prof. Dr. Aviram Nissan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • esophageal cancer
  • immunotherapy
  • PIPAC
  • HER2

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 505 KiB  
Article
The Impact of Overweight and Obesity on Reduced-Port Laparoscopic Distal Gastrectomy for Gastric Cancer Patients: A Propensity Score Matching Analysis of a Single-Institution Data
by Ho-Goon Kim, Dong-Yeon Kang and Dong-Yi Kim
J. Clin. Med. 2022, 11(21), 6453; https://doi.org/10.3390/jcm11216453 - 31 Oct 2022
Cited by 1 | Viewed by 1460
Abstract
This study aimed to investigate the short-term postoperative outcomes of reduced-port laparoscopic distal gastrectomy and demonstrate its safety and feasibility in overweight and obese patients with gastric cancer. The medical records of 211 patients who underwent reduced-port laparoscopic distal gastrectomy, between August 2014 [...] Read more.
This study aimed to investigate the short-term postoperative outcomes of reduced-port laparoscopic distal gastrectomy and demonstrate its safety and feasibility in overweight and obese patients with gastric cancer. The medical records of 211 patients who underwent reduced-port laparoscopic distal gastrectomy, between August 2014 and April 2020, were reviewed. After propensity score matching, they were divided into a non-overweight group (n = 68) and overweight group (n = 68). Operative details and short-term surgical outcomes were compared between two groups. Reduced-port laparoscopic distal gastrectomy in overweight group showed statistically longer operation time (200.59 vs. 208.68 min, p = 0.044), higher estimated bleeding volume (40.96 vs. 58.01 mL, p = 0.001), and lesser number of harvested lymph nodes (36.81 vs. 32.13, p = 0.039). However, no significant differences were found in hospital course and other surgical outcomes. There was no mortality in either group, and the postoperative morbidity rate was not significantly different (14.7% vs. 16.2%). In the subgroup analysis, overweight and obesity did not significantly affect postoperative complication rates (16.2% vs. 16.2%, p = 1). We demonstrated comparable short-term surgical outcomes of reduced-port laparoscopic distal gastrectomy between the two groups (p = 0.412~1). Reduced-port laparoscopic distal gastrectomy was safe in overweight and obese patients with gastric cancer. Full article
(This article belongs to the Special Issue Advances in Treatment of Gastroesophageal Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

23 pages, 2897 KiB  
Systematic Review
Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis
by Danny Conde Monroy, Milciades Ibañez-Pinilla, Juan Carlos Sabogal, Carlos Rey Chaves, Andrés Isaza-Restrepo, Felipe Girón, Marco Vanegas, Rafael Ibañez-Villalba, Lutz Mirow and Timo Siepmann
J. Clin. Med. 2023, 12(2), 704; https://doi.org/10.3390/jcm12020704 - 16 Jan 2023
Cited by 7 | Viewed by 3233
Abstract
Gastric cancer liver metastasis (GCLM) is a contraindication for surgical treatment in current guidelines. However, the results of recent studies are questioning this paradigm. We assessed survival outcomes and their predictors following hepatectomy for GCLM in a systematic review of studies published from [...] Read more.
Gastric cancer liver metastasis (GCLM) is a contraindication for surgical treatment in current guidelines. However, the results of recent studies are questioning this paradigm. We assessed survival outcomes and their predictors following hepatectomy for GCLM in a systematic review of studies published from 2000 to 2022 according to PRISMA guidelines. We identified 42,160 references in four databases. Of these, 55 articles providing data from 1990 patients fulfilled our criteria and were included. We performed a meta-analysis using random-effects models to assess overall survival (OS) and disease-free survival (DFS) at one, three, and five years post-surgery. We studied the impact of potential prognostic factors on survival outcomes via meta-regression. One, three, and five years after surgery, OS was 69.79%, 34.79%, and 24.68%, whereas DFS was 41.39%, 23.23%, and 20.18%, respectively. Metachronous presentation, well-to-moderate differentiation, small hepatic tumoral size, early nodal stage, R0 resection, unilobar compromisation, and solitary lesions were associated with higher overall survival. Metachronous presentation, smaller primary tumoral size, and solitary metastasis were linked to longer DFS. The results of our meta-analysis suggest that hepatectomy leads to favorable survival outcomes in patients with GCLM and provides data that might help select patients who will benefit most from surgical treatment. Full article
(This article belongs to the Special Issue Advances in Treatment of Gastroesophageal Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop